Abstract
Circulating cell-free tumor DNA (ctDNA) released from apoptotic or necrotic sold tumor cells, such as
breast cancer, into the bloodstream. Breast cancer patients show high levels of circulating DNA shed from
the tumor compared to healthy individuals. This case-control study involved 35 women diagnosed with
breast cancer and 50 healthy controls. Blood samples were processed for serum and plasma, utilizing
K3_EDTA tubes for ctDNA extraction and gel tubes for ELISA assays. The study assessed the evaluation
of the TP53 and BRCA2 proteins from serum using ELISA kits. CtDNA was extracted from plasma using
a special kit and real-time PCR (RT-qPCR) to quantify the levels of TP53 and BRCA2. The purpose of this
study is to explore the advancements in ctDNA detection technologies, monitor disease progression, and
provide insight into the genetic landscape of breast cancer in Iraqi patients, suggesting the ctDNA of BRCA2
and TP53 potential as valuable biomarkers for diagnosis and treatment monitoring. The results identified
several important findings regarding breast cancer patients and their healthy control counterparts, in terms
of genetic markers, serum BRCA2 levels showed (327.02) in breast cancer patients which is significantly
lower compared to controls (511.85) and serum TP53 levels followed a similar trend (198.41) in breast
cancer group and (389.57) in control group. DNA concentration analysis which is ctDNA showed (2.440)
DNA level of BRCA2 gene in breast cancer patients, compared to controls (1.000). On the other hand, DNA
level of TP53 gene was (0.191), significantly lower in breast cancer patients compared to controls (1.000).
These findings highlight the importance of using ctDNA and molecular markers in improving personalized
cancer treatment
breast cancer, into the bloodstream. Breast cancer patients show high levels of circulating DNA shed from
the tumor compared to healthy individuals. This case-control study involved 35 women diagnosed with
breast cancer and 50 healthy controls. Blood samples were processed for serum and plasma, utilizing
K3_EDTA tubes for ctDNA extraction and gel tubes for ELISA assays. The study assessed the evaluation
of the TP53 and BRCA2 proteins from serum using ELISA kits. CtDNA was extracted from plasma using
a special kit and real-time PCR (RT-qPCR) to quantify the levels of TP53 and BRCA2. The purpose of this
study is to explore the advancements in ctDNA detection technologies, monitor disease progression, and
provide insight into the genetic landscape of breast cancer in Iraqi patients, suggesting the ctDNA of BRCA2
and TP53 potential as valuable biomarkers for diagnosis and treatment monitoring. The results identified
several important findings regarding breast cancer patients and their healthy control counterparts, in terms
of genetic markers, serum BRCA2 levels showed (327.02) in breast cancer patients which is significantly
lower compared to controls (511.85) and serum TP53 levels followed a similar trend (198.41) in breast
cancer group and (389.57) in control group. DNA concentration analysis which is ctDNA showed (2.440)
DNA level of BRCA2 gene in breast cancer patients, compared to controls (1.000). On the other hand, DNA
level of TP53 gene was (0.191), significantly lower in breast cancer patients compared to controls (1.000).
These findings highlight the importance of using ctDNA and molecular markers in improving personalized
cancer treatment
Keywords
BRCA2
Breast Cancer
circulating tumor DNA
ELISA.
TP53